Levetiracetam and Deafness bilateral - a phase IV clinical study of FDA data

Summary:

Deafness bilateral is reported as a side effect among people who take Levetiracetam (levetiracetam), especially for people who are male, 50-59 old, have been taking the drug for 6 - 12 months also take Methotrexate, and have Foetal exposure during pregnancy.

The phase IV clinical study analyzes which people have Deafness bilateral when taking Levetiracetam. It is created by eHealthMe based on reports of 74,747 people who have side effects when taking Levetiracetam from the FDA, and is updated regularly.

What is Levetiracetam?

Levetiracetam has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 75,292 Levetiracetam users. Check the latest studies of Levetiracetam.

What is Deafness bilateral?

Deafness bilateral is found to be associated with 200 drugs and 749 conditions by eHealthMe. Check the latest studies of Deafness bilateral.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

74,747 people reported to have side effects when taking Levetiracetam.
Among them, 12 people (0.02%) have Deafness bilateral.

Could Levetiracetam cause Deafness bilateral?

Among these 12 people:

How long have people been on Levetiracetam when they have Deafness bilateral? *

What is the gender of people who have Deafness bilateral when taking Levetiracetam? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Deafness bilateral when taking Levetiracetam? *

What are other drugs people take besides Levetiracetam? *

What are other side effects people have besides Deafness bilateral? *

Tremor (trembling or shaking movements in one or more parts of your body): 5 people, 41.67%
Asthma: 5 people, 41.67%
Aggression: 5 people, 41.67%
Weight Decreased: 4 people, 33.33%
Communication Disorder (speech and language disorder): 4 people, 33.33%
Eating Disorder: 4 people, 33.33%
Mood Swings (an extreme or rapid change in mood): 4 people, 33.33%
Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 4 people, 33.33%
Cerebral Disorder (brain disease): 4 people, 33.33%
Low Set Ears (depressed positioning of the pinna (outer ear )): 4 people, 33.33%

What are the existing conditions these people have? *

Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 2 people, 16.67%
Sleep Disorder: 1 person, 8.33%
Confusional State: 1 person, 8.33%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 1 person, 8.33%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 8.33%
Bipolar Disorder (mood disorder): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Levetiracetam and have Deafness bilateral?

- Check whether Deafness bilateral is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Levetiracetam:

Levetiracetam (75,292 reports)

Browse all side effects of Levetiracetam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deafness bilateral:

Deafness bilateral (200 drugs)

Browse all the conditions that are associated with Deafness bilateral:

Deafness bilateral (749 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Levetiracetam) and Levetiracetam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.